Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05554289
Other study ID # ICBT2021
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 21, 2023
Est. completion date December 31, 2023

Study information

Verified date September 2022
Source Adai Technology (Beijing) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this clinical trial is to evaluate the clinical efficacy and safety of adjuvant intervention therapy software for depression in patients with mild to moderate depression


Description:

The main purpose of this clinical trial is to evaluate the clinical efficacy and safety of adjuvant intervention therapy software for depression in patients with mild to moderate depression under the premise of ensuring the safety of the subjects and ensuring the scientificity of the clinical trial.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 456
Est. completion date December 31, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patients voluntarily participate in the trial and sign the informed consent; 2. Age 18-60 years old (including 18 years old and 60 years old), gender is not limited; 3. The clinical diagnosis complies with the diagnostic criteria for depression in the "Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, DSM-5" (through the International Neuropsychiatry Brief Interview Questionnaire (Mini- International Neuropsychiatric Interview, M.I.N.I.) confirming the diagnosis) without psychotic symptoms; 4. Patients with Montgomery Depression Rating Scale (MADRS) score greater than or equal to 12 and less than 30 at screening; 5. Patients who have not received antidepressant systemic treatment within 2 weeks before screening, and who can maintain no need for antidepressant treatment during the trial period as assessed by the research doctor; or take serotonin reuptake stably for at least 6 weeks before screening Inhibitor (Selective Serotonin Reuptake Inhibitor, SSRI) class, or serotonin and norepinephrine reuptake dual inhibitor (Serotonin-Norepinephrine Reuptake Inhibitor, SNRI) class, or noradrenergic and specific serotonergic Antidepressants (Noradrenergic and Specific Serotonergic Antidepressants, NaSSA) antidepressants, and the medication compliance is 80%-120% and the drug dose adjustment is less than 20%, and the antidepressant treatment can be maintained during the trial period as assessed by the clinician patients on the original treatment regimen; 6. Patients with primary school education or above, who can understand the content of the scale and can use smart phones proficiently. Exclusion Criteria: 1. Patients whose clinical diagnosis meets the diagnostic criteria for other mental disorders except depression in DSM-5 (diagnosis confirmed by M.I.N.I.); 2. Patients with refractory depression (those who have been treated with 2 or more antidepressants with different chemical structures in the past or currently, and who have been treated with a sufficient dose and a full course of treatment (at least 4 weeks according to the maximum dose in the instructions) are ineffective); 3. Patients with a history of alcohol and drug dependence; 4. Pregnant or breastfeeding female patients, or male or female patients with reproductive plans during clinical trials; 5. Those with 10. Suicidal ideation score of MADRS score greater than or equal to 4 points, that is, those with severe suicidal ideation or suicide attempt; 6. Patients received other antidepressant treatment methods within 3 months before enrollment, including traditional Chinese medicine, modified electroconvulsive therapy (MECT), transcranial magnetic stimulation, biofeedback therapy, phototherapy, acupuncture and other physical therapy and system psychology treat; 7. Severe physical disease, severe liver, renal insufficiency and thyroid disease (Alanine Aminotransferase (ALT), or Aspartate Aminotransferase (AST) exceeds the upper limit of normal twice at screening, or total Bilirubin (Total Bilirubin, TBIL) exceeds 1.5 times the upper limit of normal; Creatinine (CR) exceeds 1.2 times the upper limit of normal; Thyroid Stimulating Hormone (TSH) exceeds the upper limit of normal), or as judged by the investigator Patients with other diseases who are not suitable for inclusion in this trial; upon the judgment of the investigator, a re-examination of non-compliant laboratory tests is allowed, but the re-examination must be completed within the screening period; 8. Patients who clearly express their unwillingness to participate in psychotherapy, or who think that psychotherapy is ineffective; 9. Patients who have participated in or are participating in drug clinical trials within 3 months before screening, or patients who have participated in or are participating in other device clinical trials within 1 month before screening; 10. Other conditions judged by the investigator to be unsuitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Depression Auxiliary Intervention Treatment Software
Depression Auxiliary Intervention Treatment Software

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Adai Technology (Beijing) Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Montgomery-Asberg Depression Rating Scale Montgomery-Asberg Depression Rating Scale.The maximum value of the Montgomery-Asberg Depression Rating Scale is 60, and the minimum value of the Montgomery-Asberg Depression Rating Scale is 0.Higher scores mean a worse outcome. 56 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A